Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
03 2019
Historique:
received: 04 07 2018
accepted: 31 01 2019
pubmed: 15 3 2019
medline: 30 10 2019
entrez: 15 3 2019
Statut: ppublish

Résumé

The rates and routes of lethal systemic spread in breast cancer are poorly understood owing to a lack of molecularly characterized patient cohorts with long-term, detailed follow-up data. Long-term follow-up is especially important for those with oestrogen-receptor (ER)-positive breast cancers, which can recur up to two decades after initial diagnosis

Identifiants

pubmed: 30867590
doi: 10.1038/s41586-019-1007-8
pii: 10.1038/s41586-019-1007-8
pmc: PMC6647838
mid: NIHMS1520488
doi:

Substances chimiques

Receptors, Estrogen 0
ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

399-404

Subventions

Organisme : NCI NIH HHS
ID : DP1 CA238296
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Lancet. 1991 Aug 10;338(8763):327-31
pubmed: 1677695
BMC Med Res Methodol. 2013 Jun 20;13:80
pubmed: 23786493
Genome Biol. 2014 Aug 28;15(8):431
pubmed: 25164602
Bioinformatics. 2011 Nov 15;27(22):3206-8
pubmed: 21903630
Genome Biol. 2013 Apr 29;14(4):R34
pubmed: 23618380
J Natl Cancer Inst. 2013 Oct 2;105(19):1504-11
pubmed: 24029245
Cancer Res. 2008 Jul 1;68(13):5405-13
pubmed: 18593943
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Nat Med. 2010 Feb;16(2):214-8
pubmed: 20098429
Breast Cancer Res Treat. 1999 Jul;56(1):67-78
pubmed: 10517344
Bioinformatics. 2012 Mar 15;28(6):882-3
pubmed: 22257669
Biom J. 2006 Jun;48(3):366-80
pubmed: 16845902
Cell. 2011 Sep 16;146(6):904-17
pubmed: 21889194
Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13550-5
pubmed: 16141321
Stat Med. 2008 Sep 20;27(21):4340-58
pubmed: 18425994
Clin Cancer Res. 2006 Nov 15;12(22):6652-62
pubmed: 17121884
J Clin Oncol. 2018 Jul 1;36(19):1941-1948
pubmed: 29676944
Breast Cancer Res Treat. 2003 Apr;78(3):323-35
pubmed: 12755491
EMBO Mol Med. 2011 Mar;3(3):167-80
pubmed: 21337521
Hum Biol. 1951 Sep;23(3):205-41
pubmed: 14880165
Bioinformatics. 2004 Feb 12;20(3):307-15
pubmed: 14960456
Breast Cancer Res Treat. 1999 Mar;54(1):83-9
pubmed: 10369084
PLoS Med. 2010 May 25;7(5):e1000279
pubmed: 20520800
Oncogene. 2012 Jul 19;31(29):3397-408
pubmed: 22105362
J Clin Oncol. 2014 Jul 1;32(19):1979-86
pubmed: 24888802
Carcinogenesis. 2013 Oct;34(10):2300-8
pubmed: 23740839
BMC Genomics. 2008 May 22;9:239
pubmed: 18498629
Breast Cancer Res Treat. 2011 Aug;128(3):827-35
pubmed: 21327471
J Clin Oncol. 1987 Jan;5(1):55-61
pubmed: 3806159
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Nat Rev Clin Oncol. 2019 May;16(5):296-311
pubmed: 30563978
Clin Cancer Res. 2007 Jun 1;13(11):3207-14
pubmed: 17545524
Bioinformatics. 2016 Apr 1;32(7):1097-9
pubmed: 26607490
N Engl J Med. 2017 Nov 9;377(19):1836-1846
pubmed: 29117498
Biom J. 2008 Jun;50(3):346-63
pubmed: 18481363
Cell. 2014 Dec 4;159(6):1461-75
pubmed: 25433701
J Clin Oncol. 2009 Mar 10;27(8):1160-7
pubmed: 19204204
Cell Rep. 2017 Feb 28;18(9):2088-2095
pubmed: 28249155
J Clin Oncol. 2016 Apr 1;34(10):1134-50
pubmed: 26858339
Lancet Oncol. 2013 Oct;14(11):1067-1076
pubmed: 24035531
Lancet. 2013 Mar 9;381(9869):805-16
pubmed: 23219286
J Clin Oncol. 2010 Jul 10;28(20):3271-7
pubmed: 20498394
Clin Breast Cancer. 2008 Jun;8(3):287-92
pubmed: 18650162
Breast Cancer Res. 2010;12(1):R1
pubmed: 20053270
Cancer Discov. 2016 Aug;6(8):838-851
pubmed: 27179038
Stat Med. 2007 May 20;26(11):2389-430
pubmed: 17031868
Stat Med. 1993 Dec 30;12(24):2315-32
pubmed: 8134735

Auteurs

Oscar M Rueda (OM)

Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.

Stephen-John Sammut (SJ)

Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.

Jose A Seoane (JA)

Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.

Suet-Feung Chin (SF)

Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.

Jennifer L Caswell-Jin (JL)

Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.

Maurizio Callari (M)

Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.

Rajbir Batra (R)

Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.

Bernard Pereira (B)

Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.

Alejandra Bruna (A)

Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.

H Raza Ali (HR)

Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.

Elena Provenzano (E)

Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK.
NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK.

Bin Liu (B)

Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.

Michelle Parisien (M)

Research Institute in Oncology and Hematology, Winnipeg, Manitoba, Canada.

Cheryl Gillett (C)

NIHR Comprehensive Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and Research Oncology, Cancer Division, King's College London, London, UK.

Steven McKinney (S)

Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.

Andrew R Green (AR)

Division of Cancer and Stem Cells, School of Medicine, University of Nottingham and Nottingham University Hospital NHS Trust, Nottingham, UK.

Leigh Murphy (L)

Research Institute in Oncology and Hematology, Winnipeg, Manitoba, Canada.

Arnie Purushotham (A)

NIHR Comprehensive Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and Research Oncology, Cancer Division, King's College London, London, UK.

Ian O Ellis (IO)

Division of Cancer and Stem Cells, School of Medicine, University of Nottingham and Nottingham University Hospital NHS Trust, Nottingham, UK.

Paul D Pharoah (PD)

Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.
Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK.
NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK.
Strangeways Research Laboratory, University of Cambridge, Cambridge, UK.

Cristina Rueda (C)

Departamento de Estadística e Investigación Operativa, Universidad de Valladolid, Valladolid, Spain.

Samuel Aparicio (S)

Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.

Carlos Caldas (C)

Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. Carlos.Caldas@cruk.cam.ac.uk.
Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK. Carlos.Caldas@cruk.cam.ac.uk.
NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK. Carlos.Caldas@cruk.cam.ac.uk.

Christina Curtis (C)

Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA. cncurtis@stanford.edu.
Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA. cncurtis@stanford.edu.
Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. cncurtis@stanford.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH